CD274 and gastric cancer: Chen et al., performed a meta-analysis for clinical trials testing the efficacy of anti-PD-1 and anti-PD-L1 ICBs in advanced gastric cancers and oesophagogastric cancers, which demonstrated that the addition of ICBs to the second- and third-line settings for treating GOCs improves some, but not all survival endpoints (Chen et al. 2019).